Skip to content
Menu

Canaccord Genuity Maintains Buy on Fractyl Health, Raises Price Target to $40

Benzinga Newsdesk 4 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and raises the price target from $39 to $40.

Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and raises the price target from $39 to $40.

Read at benzinga.com